GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,610 ($21.17) price objective by analysts at Deutsche Bank AG in a research report issued to clients and investors on Thursday. The firm currently has a “neutral” rating on the stock. Deutsche Bank AG’s price target indicates a potential upside of 6.13% from the stock’s current price.

Other analysts have also issued reports about the company. Liberum Capital reiterated a “buy” rating and set a GBX 1,900 ($24.98) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, June 14th. UBS AG set a GBX 1,600 ($21.04) price objective on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, July 26th. Bryan, Garnier & Co reiterated a “neutral” rating and set a GBX 1,710 ($22.48) price objective on shares of GlaxoSmithKline plc in a research note on Tuesday, September 19th. Credit Suisse Group reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 21st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a GBX 1,900 ($24.98) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, July 20th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of GBX 1,689.48 ($22.21).

GlaxoSmithKline plc (LON:GSK) opened at 1517.00 on Thursday. The firm’s market capitalization is GBX 74.15 billion. The firm has a 50-day moving average price of GBX 1,500.18 and a 200-day moving average price of GBX 1,586.54. GlaxoSmithKline plc has a one year low of GBX 1,444.00 and a one year high of GBX 1,724.50.

WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/12/glaxosmithkline-plc-gsk-pt-set-at-gbx-1610-by-deutsche-bank-ag.html.

In related news, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The stock was bought at an average cost of GBX 1,618 ($21.27) per share, for a total transaction of £13,930.98 ($18,315.78). Also, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The shares were bought at an average price of GBX 1,599 ($21.02) per share, with a total value of £36,249.33 ($47,658.86). Insiders bought a total of 3,153 shares of company stock valued at $5,055,853 over the last quarter.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.